DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of one of the following malignancies:

  • Hodgkin's lymphoma
  • Acute myelogenous leukemia
  • Chronic myelogenous leukemia
• Failed standard therapy or in chronic phase if on standard therapy

• At least 30% of malignant cells reactive with anti-Tac as determined by immunofluorescence studies

  • All Hodgkin's lymphoma patients eligible due to 100% Tac-positivity of Reed-Sternberg cells
• Measurable disease
• No symptomatic CNS disease

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• 0-2

Life expectancy:

• Greater than 2 months

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin no greater than 3 times normal
• No significant hepatic disease

Renal:

• Creatinine no greater than 3 times normal
• No significant renal disease

Cardiovascular:

• No significant cardiovascular disease

Pulmonary:

• No significant pulmonary disease

Other:

• No significant endocrine, rheumatologic, or allergic disease
• No HIV-I antibody
• No active disease due to any of the following:
• Cytomegalovirus Herpes simplex virus I/II
• Hepatitis B or C Tuberculosis
• Negative pregnancy test required of fertile women

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior murine anti-Tac monoclonal antibody

Chemotherapy:

• At least 4 weeks since chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• At least 4 weeks since radiotherapy

Surgery:

• Not specified

Other:

• Concurrent treatment allowed for complications of primary disease